Vismodegib, included in an ongoing Alliance clinical trial, is a hedgehog pathway-targeting agent tested for SMO/PTCH1-mutated progressive/recurrent meningiomas (NCT02523014) (32). This evidence concerns the gene SMO and meningioma.